ArticleCureus2025
When Neurology Overlaps: Herpes Simplex Virus Encephalitis in a Patient with Progressive Multiple Sclerosis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herpes simplex virus encephalitis (HSVE) is the most common cause of sporadic viral encephalitis in adults and carries significant morbidity and mortality if untreated. We report the case of a middle-aged female patient with progressive multiple sclerosis (MS) who developed acute gastrointestinal symptoms followed by rapid neuropsychiatric deterioration, expressive aphasia, and focal seizures. Initial evaluation suggested infectious gastroenteritis, hyponatraemia, and a possible MS exacerbation. Despite partial biochemical correction, her neurological status worsened. Later on, she developed focal seizures, which warranted urgent stroke and neurological review. Neuroimaging demonstrated temporal lobe and insular involvement (edema and hyperintensity in T2/Fluid Attenuated Inversion Recovery (FLAIR)), and cerebrospinal fluid (CSF) polymerase chain reaction (PCR) confirmed Herpes simplex virus (HSV)-1 infection. She was treated with intravenous acyclovir for 21 days. Although virological clearance and radiological resolution were achieved, she developed persistent neurocognitive sequelae, including aphasia, seizures, and personality changes. This case highlights the diagnostic complexity of HSVE in the context of MS, where overlapping features can obscure early recognition. Prompt initiation of acyclovir and multidisciplinary management are crucial to optimizing outcomes and minimizing long-term disability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.